Isis, GlaxoSmithKline target validation deal

GlaxoSmithKline (GSK; LSE:GSK) will use antisense inhibitors from ISIS's GeneTrove division to validate gene targets. GSK will also license certain ISIS IP for use in the pharma company's internal ant...